Pharmaceutical / Drug Definition :
Acts as competitive inhibitor at postganglionic muscarinic receptor sites of parasympathetic nervous system and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. May block cholinergic transmission from vestibular nuclei to higher CNS centers and from reticular formation to vomiting center
In the United States, Scopolamine is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Scopolamine.
Scopolamine (Scopolamine Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Scopolamine (Scopolamine Suppliers)
- Processors Scopolamine
- Repackers Scopolamine
- Relabelers Scopolamine
- Exporters Scopolamine
- Importers Scopolamine
For more information about Scopolamine, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.